ArticleAnnals of surgical oncology2026
Lack of Utility of Ki-67 in Axillary Surgical Planning and Prognostication after Neoadjuvant Chemotherapy for Node-Positive Breast Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: Predicting Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeoadjuvant chemotherapy (NAC) can downstage the axilla for patients with breast cancer and spare axillary lymph node dissection (ALND). Although tumor biomarkers help predict response to NAC and inform surgical decision-making, the role of Ki-67 in predicting axillary pathologic complete response (pCR) and recurrence is unclear.
methodsConsecutive patients with stage II/III node-positive breast cancer treated with NAC from January 2007 to July 2021 were identified from a prospective database. Ki-67 was categorized. Multivariable logistic regression identified predictors of nodal pCR and recurrence. Distant disease-free survival (DDFS) analysis was performed for changes in Ki-67 for patients with residual disease.
resultsOf 407 node-positive patients treated with NAC, 172 (42.3%) converted to ycN0. Most patients had cT2 (52.9%) and cN1 disease (90.1%). Median Ki-67 from the biopsy specimen was 43% (interquartile range 31-70); Ki-67 was highest in triple-negative disease. Overall, 105 patients (61.0%) had a nodal pCR; the rate of nodal pCR was significantly different among biomarker subtypes: 32.8% for hormone receptor-positive (HR+ )/human epidermal growth factor receptor 2-negative (HER2-), 73.3% for HR-/HER2-, 75.0% for HR+/HER2+, and 81.8% for HR-/HER2+ (p < 0.0001). There was no association between the initial Ki-67 and nodal pCR for any receptor subtype. On multivariable analysis, Ki-67 did not predict nodal pCR or recurrence; among patients with residual disease, a decrease in Ki-67 after NAC was associated with improved DDFS (hazard ratio 0.28; 95% confidence interval 0.07-1.13; Wilcoxon p = 0.02, log-rank p = 0.057).
conclusionsKi-67 was not predictive of nodal pCR and is not a useful adjunct for surgical decision-making; however, a decrease in Ki-67 from biopsy to surgical specimen may suggest improved DDFS.
Indexed as
Identifiers
42829410What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.